






Imipenem + cilastatin

NOT RECOMMENDED AS AN
ESSENTIAL MEDICINE

Section: 6. Anti-infective medicines > 6.2. Antibacterials > 6.2.2. Watch group antibiotics

		EMLc	ATC codes: J01DH51
Indication	Antibiotic resistant <i>Acinetobacter baumannii</i>	ICD11 code: MG50.0	
INN	Imipenem + cilastatin		
Medicine type	Chemical agent		
Antibiotic groups	 WATCH		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection ; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection		
EML status history	First added in 1997 (TRS 882) Changed in 2002 (TRS 914) Changed in 2007 (TRS 950) Changed in 2009 (TRS 958) Removed in 2017 (TRS 1006)		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more about patents . 		
Wikipedia	Imipenem + cilastatin 		
DrugBank	Imipenem  Cilastatin 		

Summary of evidence and Expert Committee recommendations

As part of the syndrome-based comprehensive review of antibacterials on the Model Lists, imipenem + cilastatin was removed from the EML and EMLc. However, it is acknowledged in the lists as an alternative to meropenem except for acute bacterial meningitis where meropenem is preferred.

